Cantor Fitzgerald Estimates Atyr PHARMA FY2026 Earnings

Atyr PHARMA INC (NASDAQ:ATYRFree Report) – Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Atyr PHARMA in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will earn ($0.78) per share for the year. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share.

Atyr PHARMA (NASDAQ:ATYRGet Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02.

Other equities analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Atyr PHARMA in a report on Wednesday, June 4th. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Finally, Leerink Partners assumed coverage on Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $18.60.

View Our Latest Research Report on ATYR

Atyr PHARMA Trading Down 2.0%

Shares of ATYR stock opened at $5.39 on Wednesday. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $5.98. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $3.65 and its two-hundred day moving average is $3.57. The company has a market cap of $479.73 million, a PE ratio of -5.73 and a beta of 0.88.

Institutional Investors Weigh In On Atyr PHARMA

Several hedge funds and other institutional investors have recently modified their holdings of ATYR. D.A. Davidson & CO. acquired a new stake in shares of Atyr PHARMA in the fourth quarter worth $141,000. Charles Schwab Investment Management Inc. bought a new position in Atyr PHARMA in the fourth quarter worth $144,000. Victory Capital Management Inc. bought a new position in Atyr PHARMA in the fourth quarter worth $37,000. Raymond James Financial Inc. bought a new position in Atyr PHARMA in the fourth quarter worth $39,000. Finally, Farther Finance Advisors LLC bought a new position in Atyr PHARMA in the fourth quarter worth $88,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About Atyr PHARMA

(Get Free Report)

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Recommended Stories

Earnings History and Estimates for Atyr PHARMA (NASDAQ:ATYR)

Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.